Petefeszekrakos betegek cyclophosphamide es cisplatin (CP) kombinalt kemoterapiaja Amifostine (WR-1065) vedelemben

Translated title of the contribution: Cyclophosphamide and cisplatin (CP) combined chemotherapy in Amifostine (WR 1065) protection of patients with ovarian cancer

Z. Hernadi, L. Lukacsko, T. Sapy, A. Borsos

Research output: Contribution to journalArticle

Abstract

The aim of the study was to integrate the selective cytoprotection with Amifostine into the treatment of ovarian cancer and via its administration to gain experiences regarding its side-effects and its capacity in reducing the toxicity of the components of the CP treatment. The efficacy of chemotherapy was evaluated parallel to the measurement of the remission. 53 cycles of chemotherapy of 11 advanced stage ovarian cancer patients were evaluated. The dosage of Amifostine administered 15 minutes before the standard dose CP chemotherapy was 910 mg/sqm body surface. The response was evaluated with CT and ultrasonography. We found that the administration of Amifostine before CP treatment can easily be integrated into the work of departments of chemotherapy. It does not present an additional burden on the patients or the nursing stuff. Hypotension, the only registered side-effect is rare and mild. It gets resolved spontaneously not requiring any special therapy. The most spectacular feature of the protective capacity is that the level of haemoglobin decreased only in two cycles (3,7%) below 100 g/l which is the physiological basis for the presentation of a good physical and mental performance in patients during therapy. This finding is quantitatively supported by the fact, that performance score worse than WHO G 1 was not registered in the study. The efficacy of chemotherapy was not influenced by the Amifostine pre-treatment as it is demonstrated by the high-proportion of patients with complete or partial remission (Complete remission: 7 pts, Partial remission: 1 pt, Stabilization; 2 pts, Progression: 1 pt). Our conclusion is, that the pre-treatment with Amifostine improves quality of life of patients via reducing the cummulative toxicity of the CP combination in respect to its haematological, renal and neurological toxicity without a reduction in the antitumor efficacy.

Translated title of the contributionCyclophosphamide and cisplatin (CP) combined chemotherapy in Amifostine (WR 1065) protection of patients with ovarian cancer
Original languageHungarian
Pages (from-to)489-496
Number of pages8
JournalMagyar Noorvosok Lapja
Volume61
Issue number6
Publication statusPublished - Dec 1 1998

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Cyclophosphamide and cisplatin (CP) combined chemotherapy in Amifostine (WR 1065) protection of patients with ovarian cancer'. Together they form a unique fingerprint.

  • Cite this